🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

What's the best type of brain surgery? The one that is cancelled because all of your brain mets have shrunk, including one scheduled to be removed today, in the 11 days since you started taking 1800 mg alectinib and 800 mg capmatinib. #lcsm #TTLC22

Panel at #TTLC22 covering many less common mutations chaired by Drs. Amy L. Cummings, MD PhD and Stinchcombe with panel of Drs. Ross, Wade Iams, Paik, Dr. Ravi Salgia, and Lisberg. Common themes: importance of advocacy groups and trials for less common targets (and test, test, test!) #LCSM

Neoadjuvant nivolumab plus chemotherapy FDA approved for resectable NSCLC! Based on phase III CheckMate 816 study that showed adding neoadjuvant immunotherapy increased pathologic CR (24% from 2%) and improved EFS with better surgical outcomes. #LCSM news.bms.com/news/corporate…

Proud to support Laura Greco and @lungCAN nwmd.io/s/twitter/Zh48…

If I can get through 2 brain surgeries. You can take 2 minutes to fill out. This petitionn for more lung cancer research. www.lungcam.oeg/act #lcam

Wonderful seeing friends and colleagues in person at the . retreat yesterday. Great representation by UCLA MII and Medical Informatics home area trainees showing off their AI/ML work to improve cancer prevention, detection, and diagnosis at the poster session! 📸✌️

Congrats, Dr. May! A well-deserved honor.

Most clinical health trials lack diversity, a problem that can have a negative impact on health outcomes. Maria Garcia-Jimenez, MD MHS of . & @DGSOMUCLA is working to improve cancer research diversity & helping to reduce disparities across the cancer care continuum.

Dr. Estela Rodriguez NEJM Agree 💯! Engaging with communities, building trustworthiness, and involving minority patients in clinical research design is key to addressing #disparities in #clinicaltrials participation.

Very high PDL1 is an important stratification factor in multi arm trials evaluating new IOs given differential survival for this very high group. Should be reported to ensure balanced PDL1 >=90% in control and experimental arms. Penn Medicine - Abramson Cancer Center #lcsm #IO

Back to work after a great #NCCN2023 conference! ⁦Thankful for the opportunity to highlight disparities in cancer screening alongside Dr. Kelvin Moses, Dr. Sarah McLaughlin, and Ludmilla Svoboda ⁦National Comprehensive Cancer Network (NCCN)⁩ ⁦⁦.⁩

Check out our new paper published in nature today, where we explore how the cost of ICF translation hinders LEP enrollment in non-industry studies. nature.com/articles/s4158…

My life story, thanks Dave Dave Bjork! So fun to interview with you. researchevangelist.com/podcast/episod…

This is great news for ALK+ patients with resected early lung cancer and I am very much looking forward to seeing this highly anticipated ALINA trial data BTOG

A big congrats to Dr. Eddie Garon, who was awarded two grants totaling over $3.5M from the NIH to help improve outcomes for patients with early and advanced stages of non-small cell lung cancer. uclahealth.org/news/edward-ga…

FDA Oncology's Project Equity developed an overview of clinical trial diversity from the OCE perspective. Learn more about FDA's guidance on Diversity Plans and new FDA policies. fda.gov/media/174159/d… #OCEProjectEquity

. Geffen Academy at UCLA AACR David Geffen School of Medicine at UCLA Congrats Amy L. Cummings, MD PhD and team!

Starting Now: Vaccine and Oncolytic Virus and Cellular Therapy for NSCLC Moderated by: Dr. Neal Ready Duke Cancer #DAVAHawaiiLung

Great Discussion session in CTCs and ctDNA in lung cancer as biomarkers #DAVAHawaiiLung

International Lung Cancer Congress (ILCC), now in 25th year. Nothing like it! 3 day “think tank” purposely scheduled about six weeks after ASCO. Enough time to have digested the breakthroughs and the failures, with audience response device Q & A to weigh in on the reasons. 👏👏👏